Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Bayer
- 16 Nov 2017 Planned number of patients changed from 50 to 100.
- 26 Oct 2017 Planned End Date changed from 31 Mar 2019 to 31 Aug 2019.
- 26 Oct 2017 Planned primary completion date changed from 31 Dec 2018 to 30 Jun 2019.